Stanford Develops Innovative Eye Implant Restoring Vision for the Blind

A breakthrough eye implant, developed by a scientist at Stanford University, is transforming the lives of some blind individuals by enabling them to read, identify faces, and even engage in artistic expression once more.

This innovative prosthetic, named the PRIMA retinal implant system, is more diminutive than a standard contact lens and has already facilitated significant visual improvement for numerous patients participating in European clinical trials.

Specifically targeting age-related macular degeneration, this device addresses a primary cause of vision loss among older adults, impacting approximately 1 million individuals across the United States.

Stanford’s Daniel Palanker, an ophthalmologist and electrical engineer, is the visionary behind this implant, which comprises a 2-by-2-millimeter disc embedded with 370 light-sensitive pixels, strategically positioned just behind the retina through surgical intervention.

Following implantation, patients must utilize specialized augmented-reality glasses with an integrated camera to capture images, which are then projected as near-infrared light onto the implant.

The solar-powered pixels then convert that light into electrical signals that stimulate surviving retinal cells, which send information to the brain.

After months of training, 26 out of 32 patients in a clinical trial showed significant vision gains after one year, according to results published in the New England Journal of Medicine. On average, their vision improved by an average of five lines on a standard eye chart.

Many who could previously only see the top line on the chart are now able to read large print and perform daily tasks, with one participant’s vision improving by 12 lines.

Science Corp., the Alameda-based company commercializing the technology, hopes to receive European regulatory approval this summer. Approval from US Food and Drug Administration is further down the road, but the company is pursuing a humanitarian device exemption to speed the process.

Palanker, who previously developed lasers for cataract surgery, said the key innovation was using light for both power and activation rather than wires.

“Until now, people tried restoring sight and all they got were light and shapes,” he said. “We succeeded, I think, because we properly encode information and the brain understands this information as vision.”

The device is currently being adapted for other forms of blindness, including Stargardt disease, with researchers aiming for up to five times better resolution in the next generation of the PRIMA system.

For patients, the technology offers more than restored sight — it brings back independence and joy.

“It’s huge,” said Foundation Fighting Blindness CEO Jason Menzo of the breakthrough system, which adds to an expanding field of vision restoration that includes gene therapy, stem cells and other prostheses. “The field has never ever been anywhere near as advanced as it is today.

“Just knowing there’s something out there,” Menzo added, “just the promise of the technology, whether an individual even gets the device, is lifting people’s spirits.”

Download The California Post App, follow us on social, and subscribe to our newsletters